Raymond James Financial
ENSC icon

Raymond James Financial’s Ensysce Biosciences ENSC Stock Holding History

Raymond James Financial’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-94
Closed -$210 – 5510
2025
Q2 		$210 Buy
+94
New +$215 ﹤0.01% 6778

Other funds holding ENSC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $163M AUM 18.06% 1-Year Est. Return

Raymond James Financial's ENSC Position: Q3 2025 in Review

Raymond James Financial sold out of Ensysce Biosciences (ENSC) in Q3 2025, closing a stake of 94 shares — an estimated $210 sold.

Raymond James Financial first reported a position in ENSC in Q2 2025 and held it in 1 quarter. The position peaked at $210 in Q2 2025. 17 funds tracked by Wall St. Rank hold ENSC as of Q3 2025.

  • Raymond James Financial reported no remaining Ensysce Biosciences position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 94 Ensysce Biosciences shares in Q3 2025, an estimated $210.
  • Raymond James Financial first reported a position in Ensysce Biosciences in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Ensysce Biosciences position peaked at $210 in Q2 2025.
  • 17 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.